Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.

Ng T, Mazzarello S, Wang Z, Hutton B, Dranitsaris G, Vandermeer L, Smith S, Clemons M.

Breast Cancer Res Treat. 2016 Jan;155(2):337-44. doi: 10.1007/s10549-015-3669-8. Epub 2016 Jan 5.

PMID:
26732944
2.
3.

Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.

Fraser I, Burger J, Lubbe M, Dranitsaris G, Sonderup M, Stander T.

Pharmacoeconomics. 2015 Dec 14. [Epub ahead of print]

PMID:
26666639
4.

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.

Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.

Breast Cancer Res Treat. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2. Epub 2015 Dec 7.

PMID:
26643085
5.

Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.

Adunlin G, Cyrus JW, Dranitsaris G.

Breast Cancer Res Treat. 2015 Dec;154(3):591-608. doi: 10.1007/s10549-015-3643-5. Epub 2015 Nov 23.

PMID:
26596731
6.

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G.

JAMA Oncol. 2015 Nov 12:1-7. doi: 10.1001/jamaoncol.2015.3730. [Epub ahead of print]

PMID:
26562292
7.

Economic evaluation in collaborative hospital drug evaluation reports.

Ortega A, Fraga MD, Marín-Gil R, Lopez-Briz E, Puigventós F, Dranitsaris G.

Farm Hosp. 2015 Sep 1;39(n05):288-296.

8.

Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.

Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M.

Support Care Cancer. 2015 Sep 17. [Epub ahead of print]

PMID:
26381427
9.

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.

Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH.

J Immunother. 2015 Sep;38(7):259-66. doi: 10.1097/CJI.0000000000000089.

PMID:
26261889
10.

Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.

Hernandez Torres C, Mazzarello S, Ng T, Dranitsaris G, Hutton B, Smith S, Munro A, Jacobs C, Clemons M.

Support Care Cancer. 2015 Nov;23(11):3341-59. doi: 10.1007/s00520-015-2801-y. Epub 2015 Jun 25.

PMID:
26108169
11.

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.

Dranitsaris G, Yu B, King J, Kaura S, Zhang A.

Clinicoecon Outcomes Res. 2015 May 12;7:249-56. doi: 10.2147/CEOR.S82194. eCollection 2015.

12.

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy.

Makarenko S, Dranitsaris G, Peixoto RD, Ruan JY, Cheung WY.

J Community Support Oncol. 2014 Nov;12(11):394-400. doi: 10.12788/jcso.0085.

PMID:
25856012
13.

Management of patients with Cushing's disease: a Canadian cost of illness analysis.

Uum SV, Hurry M, Petrella R, Koch C, Dranitsaris G, Lacroix A.

J Popul Ther Clin Pharmacol. 2014;21(3):e508-17. Epub 2014 Nov 28.

14.

Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.

Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H.

Clin Ther. 2015 Jan 1;37(1):134-44. doi: 10.1016/j.clinthera.2014.10.023. Epub 2014 Nov 26.

PMID:
25433768
15.

Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.

Dranitsaris G, Yu B, Wang L, Sun W, Zhou Y, King J, Kaura S, Zhang A, Yuan P.

J Oncol Pharm Pract. 2014 Oct 14. pii: 1078155214556008. [Epub ahead of print]

PMID:
25316611
16.

Health technology assessment of cancer drugs in Canada, the United kingdom and Australia: should the United States take notice?

Dranitsaris G, Papadopoulos G.

Appl Health Econ Health Policy. 2015 Jun;13(3):291-302. doi: 10.1007/s40258-014-0130-9.

PMID:
25274258
17.

What is a new drug worth? An innovative model for performance-based pricing.

Dranitsaris G, Dorward K, Owens RC, Schipper H.

Eur J Cancer Care (Engl). 2015 May;24(3):313-20. doi: 10.1111/ecc.12240. Epub 2014 Sep 25.

PMID:
25256668
18.

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Dranitsaris G, Lacouture ME.

Breast Cancer Res Treat. 2014 Oct;147(3):631-8. doi: 10.1007/s10549-014-3126-0. Epub 2014 Sep 13.

19.

Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, Marghoob AA, Carvajal RD, Chapman PB, Lacouture ME.

Cancer. 2015 Jan 1;121(1):60-8. doi: 10.1002/cncr.28980. Epub 2014 Sep 3.

20.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk